Enanta Pharmaceuticals develops small-molecule antivirals and treatments for viral infections and liver disease. It is best known for HCV protease-inhibitor chemistry that contributed to marketed hepatitis C regimens through a partnership with AbbVie. Its pipeline has centered on respiratory syncytial virus (RSV), hepatitis B, and other infectious-disease targets for specialty and primary-care physicians.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 14.9 | — | -22.6 | — |
| Q2 2025 | 18.3 | — | -18.3 | — |
| Q3 2025 | 15.1 | — | -18.7 | — |
| Q4 2025 | 18.6 | — | -11.9 | — |
| Q1 2026 | 17.2 | 15% | -13.1 | — |
| Q2 2026 | 14.4 | -21.6% | -19.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: John Marshall Bancorp, Inc. (JMSB), CSLM Digital Asset Acquisition Corp III, Ltd (KOYN), Terrestrial Energy Inc. (IMSR), StealthGas Inc. (GASS), TJGC Group Limited (TJGC), Perimeter Acquisition Corp. I (PMTR)